Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Mullane

Showing results (81-90 of 115) with videos related to

Pageof 12
Sort By:
American Journal of Nephrology|June 26, 2013
Renal impairment and clinical outcomes of Clostridium difficile infection in two randomized trialsKathleen M Mullane, Oliver A Cornely, Derrick W Crook, et al.
Investigational New Drugs|January 1, 1995
Phase II study of amonafide in the treatment of patients with advanced squamous cell carcinoma of the head and the neck. An Illinois Cancer Center studyF Rosen, E E Vokes, T Lad, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 17, 2011
Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infectionsKathleen M Mullane, Mark A Miller, Karl Weiss, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 1, 1995
Inhibition of neutrophil adhesion by adenosine and an adenosine kinase inhibitor. The role of selectinsG S Firestein, D A Bullough, M D Erion, et al.
Open Forum Infectious Diseases|May 9, 2017
Primary Outcomes From a Phase 3, Randomized, Double-Blind, Active-Controlled Trial of Surotomycin in Subjects With <i>Clostridium difficile</i> InfectionVicente Boix, Richard N Fedorak, Kathleen M Mullane, et al.
Mycoses|March 24, 2018
Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: Challenges and lessons of the VITAL trialJohn R Perfect, Oliver A Cornely, Markus Heep, et al.
Open Forum Infectious Diseases|February 27, 2020
Exploratory Evaluation of Bezlotoxumab on Outcomes Associated With <i>Clostridioides difficile</i> Infection in MODIFY I/II Participants With CancerOliver A Cornely, Kathleen M Mullane, Thomas Birch, et al.
The New England Journal of Medicine|September 27, 2013
CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantationFrancisco M Marty, Drew J Winston, Scott D Rowley, et al.
Thrombosis and Haemostasis|September 8, 2004
Recombinant urokinase for restoration of patency in occluded central venous access devices. A double-blind, placebo-controlled trialWilliam D Haire, Steven R Deitcher, Kathleen M Mullane, et al.
Plos One|June 25, 2015
Correlation between Circulating Fungal Biomarkers and Clinical Outcome in Invasive AspergillosisDionysios Neofytos, Radha Railkar, Kathleen M Mullane, et al.
Pageof 12

Showing results (81-90 of 115) with videos related to

Sort By:
Pageof 12
American Journal of Nephrology|June 26, 2013
Renal impairment and clinical outcomes of Clostridium difficile infection in two randomized trialsKathleen M Mullane, Oliver A Cornely, Derrick W Crook, et al.
Investigational New Drugs|January 1, 1995
Phase II study of amonafide in the treatment of patients with advanced squamous cell carcinoma of the head and the neck. An Illinois Cancer Center studyF Rosen, E E Vokes, T Lad, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 17, 2011
Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infectionsKathleen M Mullane, Mark A Miller, Karl Weiss, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 1, 1995
Inhibition of neutrophil adhesion by adenosine and an adenosine kinase inhibitor. The role of selectinsG S Firestein, D A Bullough, M D Erion, et al.
Open Forum Infectious Diseases|May 9, 2017
Primary Outcomes From a Phase 3, Randomized, Double-Blind, Active-Controlled Trial of Surotomycin in Subjects With <i>Clostridium difficile</i> InfectionVicente Boix, Richard N Fedorak, Kathleen M Mullane, et al.
Mycoses|March 24, 2018
Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: Challenges and lessons of the VITAL trialJohn R Perfect, Oliver A Cornely, Markus Heep, et al.
Open Forum Infectious Diseases|February 27, 2020
Exploratory Evaluation of Bezlotoxumab on Outcomes Associated With <i>Clostridioides difficile</i> Infection in MODIFY I/II Participants With CancerOliver A Cornely, Kathleen M Mullane, Thomas Birch, et al.
The New England Journal of Medicine|September 27, 2013
CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantationFrancisco M Marty, Drew J Winston, Scott D Rowley, et al.
Thrombosis and Haemostasis|September 8, 2004
Recombinant urokinase for restoration of patency in occluded central venous access devices. A double-blind, placebo-controlled trialWilliam D Haire, Steven R Deitcher, Kathleen M Mullane, et al.
Plos One|June 25, 2015
Correlation between Circulating Fungal Biomarkers and Clinical Outcome in Invasive AspergillosisDionysios Neofytos, Radha Railkar, Kathleen M Mullane, et al.
Pageof 12